Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses olopatadine hydrochloride and mometasone furoate nasal spray suspension (Ryaltris): 665 mcg olopatadine hydrochloride and 25 mcg mometasone furoate (as monohydrate) per delivered dose. Indication: For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.